Exelixis Inc Revenue Recognition, Sales Returns, Reserve for Sales Returns
Exelixis Inc (EXEL) reported Revenue Recognition, Sales Returns, Reserve for Sales Returns of $500.00 thousand for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-04.
Discontinued › Notes › ASU 2014-09 Transition
us-gaap:RevenueRecognitionSalesReturnsReserveForSalesReturns · last filed 2016-05-04
- Exelixis Inc revenue recognition, sales returns, reserve for sales returns for the quarter ending 2016-03-31 was $500.00K.
- Exelixis Inc revenue recognition, sales returns, reserve for sales returns for the quarter ending 2015-03-31 was $0.00.
| Period end | Revenue Recognition, Sales Returns, Reserve for Sales Returns 3 month |
|---|---|
| 2016-03-31 | $500.00K 10-Q · filed 2016-05-04 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |